A duo of experts from Weill Cornell Medicine talked about the advancements made in diffuse midline gliomas research and clinical trials that may offer new hope for improving its historically poor prognosis.
Mark M. Souweidane, MD
Advertisement
Articles by Mark M. Souweidane, MD
Advertisement
Latest Updated Articles
A Changing Clinical Landscape: Promising Therapeutic Avenues in the Treatment of DIPG and Other Diffuse Midline GliomasPublished: March 21st 2025 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
3
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
4
Analyzing Subgroup Data From the TRAILBLAZER-ALZ 2 Study of Donanemab: Brandy Matthews, MD
5
